Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 10:20 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 145,369 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Disorders Clear all

Conditions: Diabetic Macular Edema
Interventions: Experimental: Group 1 - 50mg RZ402, Experimental: Group 2 - 200mg RZ402, Experimental: Group 3 - 400mg RZ402, Placebo: Group 4 - Placebo; Drug · Other
Lead sponsor: Rezolute; Other
Eligibility: 18 Years to 75 Years
Enrollment: 94 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 32
States / cities: Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 29 more

Conditions: Opioid Use Disorder, OAT
Interventions: [11C]OMAR; Drug
Lead sponsor: Yale University; Other
Eligibility: 25 Years to 65 Years
Enrollment: 110 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Substance Abuse
Interventions: drug prevention curriculum; Other
Lead sponsor: Boston Children's Hospital; Other
Eligibility: 14 Years to 19 Years
Enrollment: 225 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Mild-to-Moderate COVID-19
Interventions: KB109 + Self Supportive Care (SSC), Self Supportive Care (SSC) Alone; Other
Lead sponsor: Kaleido Biosciences; Industry
Eligibility: 18 Years and older
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 12
States / cities: Cullman, Alabama • Los Angeles, California • Rancho Cucamonga, California + 7 more

Conditions: Acute Renal Failure
Interventions: Selective cytopheretic device (SCD); Device
Lead sponsor: SeaStar Medical; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 7
States / cities: Birmingham, Alabama • San Diego, California • Denver, Colorado + 4 more

Conditions: Alopecia Areata, Alopecia Totalis, Alopecia Universalis
Interventions: Tofacitinib; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Stanford, California

Conditions: Psychosis
Interventions: Family Focused Treatment, Enhanced Care; Behavioral
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 12 Years to 35 Years
Enrollment: 129 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 7
States / cities: Los Angeles, California • San Diego, California • New Haven, Connecticut + 4 more

Conditions: Sedentary Behavior, Sedentary Time, Breast Cancer
Interventions: Behavioral: Sit Less; Behavioral
Lead sponsor: University of California, San Diego; Other
Eligibility: 50 Years and older · Female only
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Tooth, Nonvital
Interventions: Regenerative Endodontic Procedure (REP); Other
Lead sponsor: Boston University; Other
Eligibility: 7 Years to 18 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Cocaine Abuse, Cocaine-Related Disorders
Interventions: Modafinil, Levodopa/Carbidopa, Naltrexone HCl, Placebo, Motivational Interviewing (MI), Contingency management (CM), Cognitive-Behavioral Therapy (CBT); Drug · Behavioral
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years to 55 Years
Enrollment: 101 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2012
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Hepatic Insufficiency & Healthy Subjects
Interventions: Zanubrutinib; Drug
Lead sponsor: BeiGene; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 2
States / cities: Miami, Florida • Orlando, Florida

Conditions: Shift-work Disorder
Interventions: Meal service; Other
Lead sponsor: State University of New York at Buffalo; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Chikungunya Virus
Interventions: CHIKV VLP/adjuvant, Placebo; Biological
Lead sponsor: Bavarian Nordic; Industry
Eligibility: 12 Years to 64 Years
Enrollment: 3,258 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 47
States / cities: Huntsville, Alabama • Mobile, Alabama • Tempe, Arizona + 42 more

Conditions: Lung Cancer
Interventions: Laboratory Biomarker Analysis; Other
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 241 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2016
U.S. locations: 1
States / cities: Syracuse, New York

Conditions: Heart Failure
Interventions: C-Pulse™ (Implantable Counterpulsation Therapy); Device
Lead sponsor: Nuwellis, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2018
U.S. locations: 6
States / cities: Birmingham, Alabama • Louisville, Kentucky • Saint Paul, Minnesota + 3 more

Conditions: Parkinson's Disease
Interventions: Not listed
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 5,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2026
U.S. locations: 5
States / cities: Atlanta, Georgia • Cincinnati, Ohio • Portland, Oregon + 1 more

Conditions: Attention Deficit Hyperactivity Disorder (ADHD)
Interventions: FOCAL+, VR-FOCAL+; Behavioral
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 16 Years to 19 Years
Enrollment: 204 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Non-arteritic Ischemic Optic Neuropathy, Optic Disk Drusen
Interventions: Not listed
Lead sponsor: Copenhagen University Hospital, Rigshospitalet; Other
Eligibility: 11 Years and older
Enrollment: 179 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 5
States / cities: Palo Alto, California • San Francisco, California • Boulder, Colorado + 2 more

Conditions: Fabry Disease
Interventions: Not listed
Lead sponsor: Boston Children's Hospital; Other
Eligibility: 1 Year and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2030
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Liver Fibrosis Due to NASH, MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease, Alcohol Liver Disease
Interventions: Not listed
Lead sponsor: Fibronostics USA, Inc; Other
Eligibility: 18 Years to 90 Years
Enrollment: 100 participants
Timeline: 2025
U.S. locations: 1
States / cities: Lady Lake, Florida

Conditions: Chronic Myelomonocytic Leukemia, de Novo Myelodysplastic Syndromes, Myelodysplastic Syndromes, Refractory Anemia, Refractory Anemia With Excess Blasts, Refractory Anemia With Ringed Sideroblasts, Refractory Cytopenia With Multilineage Dysplasia, Thrombocytopenia
Interventions: flow cytometry, DNA methylation analysis, cytogenetic analysis, decitabine, microarray analysis, gene expression analysis, pharmacological study, polymorphism analysis; Other · Drug · Genetic
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 2
States / cities: Cleveland, Ohio

Conditions: Osteoarthritis, Hip, Hip Disease
Interventions: MAKO THA 4.0 System; Device
Lead sponsor: American Hip Institute; Other
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Des Plaines, Illinois

Conditions: Primary Progressive Aphasia
Interventions: HD-tDCS, Sham; Device
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 45 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Hemophilia B
Interventions: Non-Interventional; Other
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 16 Years and older · Male only
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 9
States / cities: Aurora, Colorado • New Haven, Connecticut • Washington D.C., District of Columbia + 6 more

Search by objective public record fields.

Study to Evaluate the Efficacy and Safety of RZ402 in Diabetic Macular Edema (DME)

Characterization of CB1 Receptors Using [11-C]OMAR in Opioid Use Disorder

Youth Substance Use Prevention/Reduction Through Science-based Drug Abuse Education

A Clinical Study to Assess the Physiologic Effects of KB109 in Patients With COVID-19 on Gut Microbiota Structure and Function

Safety Study of a Selective Cytopheretic Device (SCD) in Patients With Acute Renal Failure

Tofacitinib for the Treatment of Alopecia Areata and Its Variants

Prevention Trial of Family Focused Treatment in Youth at Risk for Psychosis

RISE - Reduce Sitting Time Among Breast Cancer Survivors

Endodontic Regenerative Procedure for Immature Non-vital Teeth

Medications for Stopping Cocaine Dependence and Preventing Relapse

Safety and Pharmacokinetics of Zanubrutinib (BGB-3111) in Healthy Subjects and Those With Impaired Liver Function

EMS Providers' Health Initiative Study

A Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX0317 (CHIKV VLP Vaccine)

Biomarkers in Predicting Response in Patients With Early-Stage Non-Small Cell Lung Cancer Previously Treated With Adjuvant Chemotherapy

C-Pulse IDE Feasibility Study- A Heart Assist System

The Parkinson's Genetic Research Study

Improving ADHD Teen Driving - Virtual Reality

NA-AION Risk Factors: New Perspectives

Evaluation of Phenotypic Variability in Fabry Disease

Clinical Correlation Evaluation of the LIVERFASt Test for Diagnosing Important Liver Lesions of Fibrosis and Steatosis Against Magnetic Resonance Elastography (MRE) for Liver Fibrosis and MR-based Assessment of Steatosis, in Adult US Population.

Differentiation Therapy With Decitabine in Treating Patients With Myelodysplastic Syndrome

Multicenter Study for Robotic Arm-assisted THA 4.0 System: Hip Spine Relationship

HDtDCS in Logopenic Variant PPA: Effects on Language and Neural Mechanisms

A Trial That Evaluates Disease Characteristics in Hemophilia B Adult Male Participants Receiving Prophylaxis With Standard of Care Factor IX Protein (FIX) Replacement Therapy